Akums Drugs & Pharmaceuticals Ltd. has announced the launch of the world’s first Lasmiditan dispersible tablets, marking an important step forward in the treatment of acute migraine. The DCGI-approved formulation introduces a patient-friendly approach to migraine management, designed to provide faster and more convenient relief during sudden migraine attacks.
Akums’ new dispersible tablet formulation is designed to address some of the most common challenges patients face during migraine attacks. This patient-centric format is particularly useful since migraine episodes are often accompanied by symptoms such as nausea, gastric stasis, vomiting, and difficulty swallowing, which can make taking conventional tablets difficult. The dispersible formulation can be mixed in a small quantity of water, allowing for easier intake during such episodes and improving overall patient compliance.
Lasmiditan belongs to the ‘ditans’ class of anti-migraine drugs and acts as a highly selective serotonin 5-HT1F receptor agonist. With a binding affinity that is more than 440 times higher for the 5-HT1F receptor than for 5-HT1B/1D receptors, the drug works directly on sensory neurons associated with migraine pathways. Because of this targeted mechanism, Lasmiditan is often referred to as a neurally active anti-migraine agent. It is indicated for the acute treatment of migraine with or without aura in adults and is not intended for preventive therapy.
Commenting on the development, Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd., said, “Anyone who has experienced a migraine understands how suddenly and intensely it can disrupt everyday life. With the world’s first Lasmiditan dispersible tablets, we wanted to create a solution that responds to those real patient challenges. The formulation disperses quickly in water, which is especially helpful during attacks when nausea or difficulty swallowing often makes conventional tablets hard to use. At Akums, we remain committed to developing thoughtful pharmaceutical innovations that combine strong science with practical patient needs, ultimately improving the treatment experience.”
The introduction of Lasmiditan dispersible tablets marks a step forward in migraine management with a patient-friendly dosage format. At Akums, this development reflects a broader commitment to delivering high-quality, innovation-led pharmaceutical solutions through advanced manufacturing capabilities, robust R&D, and a strong focus on patient-centric formulation design, ensuring improved accessibility, compliance, and overall treatment outcomes.
